Delcath Systems, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DCTH Nasdaq 2836 www.delcath.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Delcath Systems, Inc.

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results - Jan 13th, 2025 1:00 pm
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 3rd, 2025 9:01 pm
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises - Dec 30th, 2024 1:00 pm
3 US Growth Companies To Watch With Up To 32% Insider Ownership - Dec 30th, 2024 11:01 am
Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before Long - Dec 29th, 2024 1:10 pm
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer - Dec 2nd, 2024 1:30 pm
Delcath Systems (NASDAQ:DCTH) jumps 13% this week, taking one-year gains to 330% - Dec 2nd, 2024 10:32 am
Delcath Systems Third Quarter 2024 Earnings: Beats Expectations - Nov 10th, 2024 1:08 pm
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Nov 9th, 2024 9:00 pm
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights - Nov 8th, 2024 1:00 pm
Delcath Systems to Participate in Upcoming Investor Conferences - Nov 1st, 2024 8:01 pm
Delcath Systems to Host Third Quarter 2024 Earnings Call - Oct 25th, 2024 12:30 pm
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results - Oct 17th, 2024 12:30 pm
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 20th, 2024 8:01 pm
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups - Sep 16th, 2024 12:30 pm
A US$84m Market Cap Boost Pleasing ToDelcath Systems Insiders - Sep 1st, 2024 2:09 pm
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients - Aug 28th, 2024 8:01 pm
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - Aug 28th, 2024 8:01 pm
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients - Aug 27th, 2024 12:30 pm
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors - Aug 26th, 2024 8:01 pm